4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Depression by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 1222 ongoing clinical trials involving Depression
Of the 1222 trials,421 trials are in Phase II
Furthermore, 322 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Depression by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Depression, a Central Nervous System indication. The largest number of ongoing clinical trials for Depression is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions involvedin Depression-related drug trials.

Johnson & Johnson: The leading ongoing Depression related clinical trial sponsor

Johnson & Johnson, the US-based pharmaceutical company, is the top sponsor for Depression-related ongoing clinical trials.

Shanghai Mental Health Center, National Institute of Mental Health, Tehran University of Medical Sciences, and New York State Psychiatric Institute are a few other notable clinical trial sponsors involved in Depression. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Depression

Lurasidone hydrochloride (Latuda, SM-13496), Aripiprazole (Abilify Maintena), and Brexpiprazole (Rexulti, Rxulti) are among the key marketed drugs involving Depression.

Lurasidone hydrochloride (Latuda, SM-13496) is an atypical psychotropic agent belonging to the chemical class of benzisothiazole derivatives. It functions via 5-Hydroxytryptamine Receptor 1A Agonist; 5-Hydroxytryptamine Receptor 2A Antagonist; 5-Hydroxytryptamine Receptor 7 Antagonist; D2 Dopamine Receptor Antagonist mechanism of action. It is formulated as film-coated tablets for oral route of administration and also administered through intramuscular route. Latuda is indicated for the treatment of patients with schizophrenia, as monotherapy for the treatment of patients with major depressive episodes associated with bipolar I disorder (bipolar depression), as adjunctive therapy with either lithium or valproate for the treatment of patients with major depressive episodes associated with bipolar I disorder (bipolar depression). Lurasidone hydrochloride was first approved in 2010 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by several prominent pharma giants including Sunovion Pharmaceuticals Inc.

Aripiprazole (Abilify Maintena) is an atypical antipsychotic agent. It functions via 5-Hydroxytryptamine Receptor 1A (5 HT1A or G 21 or Serotonin Receptor 1A or HTR1A) Agonist; 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A) Antagonist; D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2) Agonistmechanism of action.  It is formulated as extended release powder for suspension for intramuscular route of administration (depot). Abilify Maintena is indicated for the treatment of acutely relapsed adults with schizophrenia. Aripiprazole (Abilify maintena) is indicated for the maintenance treatment of bipolar I disorder (manic depression).Aripiprazole was first approved in 2013 and is marketed globally including the US, the UK, France, Germany, and Japan by several prominent pharma giants including Otsuka America Pharmaceutical Inc.